Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

141. Systematic review with meta analysis: Directly observed treatment is not the only solution for poor adherence and low cure of tuberculosis

Systematic review with meta analysis: Directly observed treatment is not the only solution for poor adherence and low cure of tuberculosis Directly observed treatment is not the only solution for poor adherence and low cure of tuberculosis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Directly observed treatment is not the only solution for poor adherence and low cure of tuberculosis Article Text Therapeutics/Prevention Systematic review with meta analysis Directly observed treatment is not the only solution for poor adherence and low cure of tuberculosis

Evidence-Based Medicine (Requires free registration)2015

142. Tuberculosis

Tuberculosis Tuberculosis - NICE CKS Clinical Knowledge Summaries Share Tuberculosis - Summary Tuberculosis (TB) is an infection caused by bacteria of the Mycobacterium tuberculosis complex. People are infected by inhaling the bacterium in respiratory droplets released when a person with infectious active pulmonary TB coughs. Pulmonary TB is the most common presentation. Extrapulmonary TB presents with symptoms specific to the site involved, and is a more common presentation in children, people (...) to specialist treatment. Advising that pulmonary TB can be transmitted to close contacts, and that specialist screening via contact tracing will be arranged for contacts considered to be at risk. Advising on smoking cessation and drinking moderate alcohol. Have I got the right topic? Age from 1 month onwards This CKS topic is largely based on the National Institute for Health and Care Excellence (NICE) guideline Clinical diagnosis and management of tuberculosis, and measures for its prevention and control

NICE Clinical Knowledge Summaries2015

143. [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection]

[Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection] Tests in vitro de dépistage de l'infection tuberculeuse latente par détection de production d'interféron gamma [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection] Tests in vitro de dépistage de l'infection tuberculeuse latente par détection de production d'interféron gamma [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis (...) infection] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Tests in vitro de dépistage de l'infection tuberculeuse latente par détection de production d'interféron gamma. [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection] Paris: Haute Autorité de Santé

Health Technology Assessment (HTA) Database.2015

144. Randomised controlled trial: Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment

Randomised controlled trial: Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment Article Text Therapeutics/Prevention Randomised controlled trial Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment

Evidence-Based Medicine (Requires free registration)2015

147. Tuberculosis (TB): care of the child and protection of staff and patients

Tuberculosis (TB): care of the child and protection of staff and patients Tuberculosis (TB): care of the child and protection of staff and patients | Great Ormond Street Hospital Navigation Search Search You are here Tuberculosis (TB): care of the child and protection of staff and patients Tuberculosis (TB): care of the child and protection of staff and patients Please note: that the NICE Guidance is in the process of being updated and this is expected to be published in October 2015. Update (...) of Clinical Guideline 117 Tuberculosis- clinical diagnosis, and measures for its prevention and control, incorporating PH37 Tuberculosis - Hard to reach Groups. Topics included Diagnostic procedures, Infectious diseases, Mental health/ behavioural conditions, Public health and, Respiratory. M.TB is usually caused by an organism in the mycobacterium tuberculosis complex, usually mycobacterium tuberculosis (M.TB) or mycobacterium Bovis (M. Bovis). M.TB will now be referred to as TB (Tuberculosis

Great Ormond Street Hospital2015

148. Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment.

Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment. BACKGROUND: People with active tuberculosis (TB) require six months of treatment. Some people find it difficult to complete treatment, and there are several approaches to help ensure completion. One such system relies on reminders, where the health system prompts patients to attend for appointments on time, or re-engages people who have missed or defaulted on a scheduled appointment (...) . OBJECTIVES: To assess the effects of reminder systems on improving attendance at TB diagnosis, prophylaxis, and treatment clinic appointments, and their effects on TB treatment outcomes. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register, Cochrane Effective Practice and Organization of Care Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, CINAHL, SCI-EXPANDED, SSCI, mRCT, and the Indian Journal of Tuberculosis without language restriction up to 29 August

Cochrane2014

149. A four-month gatifloxacin-containing regimen for treating tuberculosis.

A four-month gatifloxacin-containing regimen for treating tuberculosis. BACKGROUND: Shortening the course of treatment for tuberculosis would be a major improvement for case management and disease control. This phase 3 trial assessed the efficacy and safety of a 4-month gatifloxacin-containing regimen for treating rifampin-sensitive pulmonary tuberculosis. METHODS: We conducted a noninferiority, randomized, open-label, controlled trial involving patients 18 to 65 years of age with smear (...) -positive, rifampin-sensitive, newly diagnosed pulmonary tuberculosis in five sub-Saharan African countries. A standard 6-month regimen that included ethambutol during the 2-month intensive phase was compared with a 4-month regimen in which gatifloxacin (400 mg per day) was substituted for ethambutol during the intensive phase and was continued, along with rifampin and isoniazid, during the continuation phase. The primary efficacy end point was an unfavorable outcome (treatment failure, recurrence

NEJM2014

150. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. BACKGROUND: Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed. METHODS: We randomly assigned patients with newly diagnosed, smear-positive, drug-sensitive tuberculosis to one of three regimens: a control regimen that included 2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed by 4 months of daily isoniazid and rifampicin; a 4-month

NEJM2014 Full Text: Link to full Text with Trip Pro

151. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. BACKGROUND: Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month treatment of uncomplicated, smear-positive pulmonary tuberculosis. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to test the noninferiority of two moxifloxacin-containing regimens as compared with a control regimen. One group of patients received isoniazid

NEJM2014

152. Interferon-γ Release Assays for the Evaluation of Tuberculosis Infection

Interferon-γ Release Assays for the Evaluation of Tuberculosis Infection 25291583 2014 10 08 2014 10 23 2016 10 19 1538-3598 312 14 2014 Oct 08 JAMA JAMA Interferon-γ release assays for the evaluation of tuberculosis infection. 1460-1 10.1001/jama.2014.4928 Blumberg Henry M HM Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia. Kempker Russell R RR Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia. eng K23 AI103044 AI (...) . 2014 Jan;27(1):3-20 24396134 N Engl J Med. 2011 Apr 14;364(15):1441-8 21488766 BMC Infect Dis. 2011;11:264 21962029 Am J Respir Crit Care Med. 2014 Jan 1;189(1):77-87 24299555 Clin Infect Dis. 2011 Apr 15;52(8):1031-7 21460320 Adult Antitubercular Agents therapeutic use BCG Vaccine immunology Female Humans Interferon-gamma Release Tests Latent Tuberculosis diagnosis drug therapy Tuberculin Test Young Adult NIHMS669847 PMC4374979 2014 10 8 6 0 2014 10 8 6 0 2014 10 24 6 0 ppublish 25291583 1911306

JAMA2014 Full Text: Link to full Text with Trip Pro

156. Tuberculosis: difficult to treat in the case of multidrug-resistance

Tuberculosis: difficult to treat in the case of multidrug-resistance Prescrire IN ENGLISH - Spotlight ''Tuberculosis: difficult to treat in the case of multidrug-resistance'', 1 October 2014 {1} {1} {1} | | > > > Tuberculosis: difficult to treat in the case of multidrug-resistance Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Tuberculosis (...) : difficult to treat in the case of multidrug-resistance Tuberculosis caused by mycobacteria that are multidrug-resistant is difficult to treat. The choice of antibiotics is limited and not properly evaluated. Tuberculosis is a contagious infectious disease which usually attacks the lungs, progressively worsening, and is sometimes fatal. It is caused by a mycobacterium. In France, nearly 5000 new cases of tuberculosis were reported in 2011, especially among men, born outside France in 54% of cases

Prescrire2014

157. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.

Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. BACKGROUND: Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy. METHODS: For this pragmatic randomised double-blind, placebo (...) -controlled trial in Khayelitsha, South Africa, we randomly assigned (1:1) patients to receive either isoniazid preventive therapy or a placebo for 12 months (could be completed during 15 months). Randomisation was done with random number generator software. Participants, physicians, and pharmacy staff were masked to group assignment. The primary endpoint was time to development of incident tuberculosis (definite, probable, or possible). We excluded tuberculosis at screening by sputum culture. We did

Lancet2014

158. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline. BACKGROUND: Bedaquiline (Sirturo, TMC207), a diarylquinoline that inhibits mycobacterial ATP synthase, has been associated with accelerated sputum-culture conversion in patients with multidrug-resistant tuberculosis, when added to a preferred background regimen for 8 weeks. METHODS: In this phase 2b trial, we randomly assigned 160 patients with newly diagnosed, smear-positive, multidrug-resistant tuberculosis to receive (...) , 1.57 to 3.80; P<0.001 by Cox regression analysis) and increased the rate of culture conversion at 24 weeks (79% vs. 58%, P=0.008) and at 120 weeks (62% vs. 44%, P=0.04). On the basis of World Health Organization outcome definitions for multidrug-resistant tuberculosis, cure rates at 120 weeks were 58% in the bedaquiline group and 32% in the placebo group (P=0.003). The overall incidence of adverse events was similar in the two groups. There were 10 deaths in the bedaquiline group and 2

NEJM2014

159. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. BACKGROUND: The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis, and malaria through the formulation of Millennium Development Goal (MDG) 6. The Global Burden of Disease 2013 study provides a consistent and comprehensive approach to disease estimation for between 1990 and 2013 (...) to select epidemic curves most consistent with prevalence data and demographic data for all-cause mortality. We analysed counterfactual scenarios for HIV to assess years of life saved through prevention of mother-to-child transmission (PMTCT) and ART. For tuberculosis, we analysed vital registration and verbal autopsy data to estimate mortality using cause of death ensemble modelling. We analysed data for corrected case-notifications, expert opinions on the case-detection rate, prevalence surveys

Lancet2014 Full Text: Link to full Text with Trip Pro

160. Diagnosis of childhood tuberculosis and host RNA expression in Africa.

Diagnosis of childhood tuberculosis and host RNA expression in Africa. BACKGROUND: Improved diagnostic tests for tuberculosis in children are needed. We hypothesized that transcriptional signatures of host blood could be used to distinguish tuberculosis from other diseases in African children who either were or were not infected with the human immunodeficiency virus (HIV). METHODS: The study population comprised prospective cohorts of children who were undergoing evaluation for suspected (...) tuberculosis in South Africa (655 children), Malawi (701 children), and Kenya (1599 children). Patients were assigned to groups according to whether the diagnosis was culture-confirmed tuberculosis, culture-negative tuberculosis, diseases other than tuberculosis, or latent tuberculosis infection. Diagnostic signatures distinguishing tuberculosis from other diseases and from latent tuberculosis infection were identified from genomewide analysis of RNA expression in host blood. RESULTS: We identified a 51

NEJM2014 Full Text: Link to full Text with Trip Pro